Galmed Granted “Preferred Technological Enterprise” Status Which may Provide the Company With Significant Financial Benefits

February 7, 2018

Responsive image

TEL AVIV, Israel, Feb. 7, 2018 /PRNewswire/ — Galmed Pharmaceuticals, Ltd. (Nasdaq: GLMD), (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other…

Category: Precious Metals